Denali Therapeutics Inc. (DNLI)

NASDAQ: DNLI · Real-Time Price · USD

24.57

-0.36 (-1.44%)

At close: Aug 26, 2026, 4:00 PM EDT

24.35

-0.22 (-0.90%)

After-hours: Aug 26, 2026, 5:20 PM EDT

Denali Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	201.53	205.33	174.96	127.11	218.04	293.48
Short-Term Investments	508.94	662.55	657.37	907.41	1,118	571.93
Cash & Short-Term Investments	710.47	867.88	832.33	1,035	1,336	865.41
Cash Growth	-20.97%	4.27%	-19.54%	-22.58%	54.40%	-41.12%
Accounts Receivable	3.93	2.18	2.17	3.42	9.28	-
Other Receivables	1.5	-	-	-	-	1.23
Receivables	5.43	2.18	2.17	3.42	9.28	1.23
Prepaid Expenses	33.89	30.6	29.93	26.21	26.82	30.6
Total Current Assets	753.93	900.66	864.44	1,064	1,372	897.23
Property, Plant & Equipment	113.42	119.94	125.63	71.64	74.52	69.61
Long-Term Investments	244.53	113.32	374.37	-	-	425.45
Other Long-Term Assets	10.83	10.94	9.74	18.14	13.4	11.87
Total Assets	1,158	1,145	1,374	1,154	1,460	1,404

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	11.81	3.33	11.14	9.48	2.79	4.78
Accrued Expenses	48.12	64.37	64.91	61.24	59.37	47.71
Current Portion of Leases	10.18	9.55	12.03	7.26	7.32	5.45
Current Unearned Revenue	-	-	-	-	290.05	320.3
Other Current Liabilities	19.98	21.1	14.13	-	4.39	-
Total Current Liabilities	90.08	98.35	102.21	77.98	363.92	378.25
Long-Term Leases	27.51	32.74	42.29	44.98	53.03	58.55
Long-Term Unearned Revenue	-	-	-	-	0.48	4.69
Other Long-Term Liabilities	205.19	-	-	-	0.38	0.38
Total Liabilities	322.78	131.09	144.5	122.96	417.81	441.87

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	1.92	1.89	1.77	1.71	1.69	1.55
Additional Paid-In Capital	3,143	3,063	2,765	2,145	2,019	1,608
Retained Earnings	-2,308	-2,052	-1,539	-1,116	-970.99	-645
Comprehensive Income & Other	-1.97	0.68	2.02	0.64	-6.89	-2.5
Total Common Equity	835.18	1,014	1,230	1,031	1,042	962.29
Shareholders' Equity	835.18	1,014	1,230	1,031	1,042	962.29
Total Liabilities & Equity	1,158	1,145	1,374	1,154	1,460	1,404

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	37.69	42.29	54.32	52.24	60.35	64.01
Net Cash (Debt)	902.32	923.91	1,137	982.27	1,276	1,227
Net Cash Growth	-2.92%	-18.77%	15.79%	-23.01%	4.00%	-14.42%
Net Cash Per Share	5.00	5.35	6.92	7.15	10.16	10.10
Filing Date Shares Outstanding	159.85	158.59	145.22	139.16	136.68	122.83
Total Common Shares Outstanding	159.76	156.18	144.22	138.39	135.97	122.28
Working Capital	663.84	802.31	762.23	986.16	1,008	518.99
Book Value Per Share	5.23	6.49	8.53	7.45	7.67	7.87
Tangible Book Value	799.93	1,014	1,230	1,031	1,042	962.29
Tangible Book Value Per Share	5.01	6.49	8.53	7.45	7.67	7.87
Machinery	-	67.54	60.37	50.35	37.6	32.97
Leasehold Improvements	-	47.76	46.91	41.24	43.7	35.24

SEC Filings: 10-K · 10-Q